114 related articles for article (PubMed ID: 25750293)
1. TSU-68 ameliorates hepatocellular carcinoma growth by inhibiting microenvironmental platelet-derived growth factor signaling.
Hara Y; Yamashita T; Oishi N; Nio K; Hayashi T; Nomura Y; Yoshida M; Hayashi T; Hashiba T; Asahina Y; Kondo M; Okada H; Sunagozaka H; Honda M; Kaneko S
Anticancer Res; 2015 Mar; 35(3):1423-31. PubMed ID: 25750293
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic effects of the PKR inhibitor C16 suppressing tumor proliferation and angiogenesis in hepatocellular carcinoma in vitro and in vivo.
Watanabe T; Ninomiya H; Saitou T; Takanezawa S; Yamamoto S; Imai Y; Yoshida O; Kawakami R; Hirooka M; Abe M; Imamura T; Hiasa Y
Sci Rep; 2020 Mar; 10(1):5133. PubMed ID: 32198380
[TBL] [Abstract][Full Text] [Related]
3. Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis.
Chen ZY; Shi M; Peng LX; Wei W; Li XJ; Guo ZX; Li SH; Zhong C; Qian CN; Guo RP
J Transl Med; 2012 Dec; 10():245. PubMed ID: 23228017
[TBL] [Abstract][Full Text] [Related]
4. A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma.
Kanai F; Yoshida H; Tateishi R; Sato S; Kawabe T; Obi S; Kondo Y; Taniguchi M; Tagawa K; Ikeda M; Morizane C; Okusaka T; Arioka H; Shiina S; Omata M
Cancer Chemother Pharmacol; 2011 Feb; 67(2):315-24. PubMed ID: 20390419
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib mesylate inhibits proliferation of human colonic stromal fibroblasts in vitro and in vivo.
Wang ZH; Li Q; Ruan SQ; Xiao Q; Liu Y; Hu YT; Hu LF; Chen HY; Zheng S; Zhang SZ; Ding KF
J Zhejiang Univ Sci B; 2014 Aug; 15(8):701-12. PubMed ID: 25091988
[TBL] [Abstract][Full Text] [Related]
6. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
[TBL] [Abstract][Full Text] [Related]
7. Transforming growth factor-beta1-induced proliferation of the prostate cancer cell line, TSU-Pr1: the role of platelet-derived growth factor.
Sintich SM; Lamm ML; Sensibar JA; Lee C
Endocrinology; 1999 Aug; 140(8):3411-5. PubMed ID: 10433194
[TBL] [Abstract][Full Text] [Related]
8. A randomised phase II study of TSU-68 in patients with hepatocellular carcinoma treated by transarterial chemoembolisation.
Inaba Y; Kanai F; Aramaki T; Yamamoto T; Tanaka T; Yamakado K; Kaneko S; Kudo M; Imanaka K; Kora S; Nishida N; Kawai N; Seki H; Matsui O; Arioka H; Arai Y
Eur J Cancer; 2013 Sep; 49(13):2832-40. PubMed ID: 23764238
[TBL] [Abstract][Full Text] [Related]
9. Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma.
Kim R; Emi M; Arihiro K; Tanabe K; Uchida Y; Toge T
Cancer; 2005 May; 103(9):1800-9. PubMed ID: 15786421
[TBL] [Abstract][Full Text] [Related]
10. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models.
Matsuki M; Hoshi T; Yamamoto Y; Ikemori-Kawada M; Minoshima Y; Funahashi Y; Matsui J
Cancer Med; 2018 Jun; 7(6):2641-2653. PubMed ID: 29733511
[TBL] [Abstract][Full Text] [Related]
11. Small molecule receptor tyrosine kinase inhibitor of platelet-derived growth factor signaling (SU9518) modifies radiation response in fibroblasts and endothelial cells.
Li M; Ping G; Plathow C; Trinh T; Lipson KE; Hauser K; Krempien R; Debus J; Abdollahi A; Huber PE
BMC Cancer; 2006 Mar; 6():79. PubMed ID: 16556328
[TBL] [Abstract][Full Text] [Related]
12. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor-binding protein-3 inhibits IGF-1-induced proliferation of human hepatocellular carcinoma cells by controlling bFGF and PDGF autocrine/paracrine loops.
Ma Y; Han CC; Li Y; Wang Y; Wei W
Biochem Biophys Res Commun; 2016 Sep; 478(2):964-9. PubMed ID: 27521890
[TBL] [Abstract][Full Text] [Related]
14. c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma.
You H; Ding W; Dang H; Jiang Y; Rountree CB
Hepatology; 2011 Sep; 54(3):879-89. PubMed ID: 21618573
[TBL] [Abstract][Full Text] [Related]
15. RNA interference against platelet-derived growth factor receptor α mRNA inhibits fibroblast transdifferentiation in skin lesions of patients with systemic sclerosis.
Liu T; Zhang J; Zhang J; Mu X; Su H; Hu X; Liu W; Zhao E; Li W
PLoS One; 2013; 8(4):e60414. PubMed ID: 23577108
[TBL] [Abstract][Full Text] [Related]
16. Transactivation of the TIEG1 confers growth inhibition of transforming growth factor-β-susceptible hepatocellular carcinoma cells.
Jiang L; Lai YK; Zhang JF; Chan CY; Lu G; Lin MC; He ML; Li JC; Kung HF
World J Gastroenterol; 2012 May; 18(17):2035-42. PubMed ID: 22563190
[TBL] [Abstract][Full Text] [Related]
17. Targeting stromal cells for the treatment of platelet-derived growth factor C-induced hepatocellular carcinogenesis.
Campbell JS; Johnson MM; Bauer RL; Hudkins KL; Gilbertson DG; Riehle KJ; Yeh MM; Alpers CE; Fausto N
Differentiation; 2007 Nov; 75(9):843-52. PubMed ID: 17999742
[TBL] [Abstract][Full Text] [Related]
18. Beta-platelet-derived growth factor receptor mediates motility and growth of Ewing's sarcoma cells.
Uren A; Merchant MS; Sun CJ; Vitolo MI; Sun Y; Tsokos M; Illei PB; Ladanyi M; Passaniti A; Mackall C; Toretsky JA
Oncogene; 2003 Apr; 22(15):2334-42. PubMed ID: 12700668
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib (SUTENT, SU11248) suppresses tumor growth and induces apoptosis in xenograft models of human hepatocellular carcinoma.
Huynh H; Ngo VC; Choo SP; Poon D; Koong HN; Thng CH; Toh HC; Zheng L; Ong LC; Jin Y; Song IC; Chang AP; Ong HS; Chung AY; Chow PK; Soo KC
Curr Cancer Drug Targets; 2009 Sep; 9(6):738-47. PubMed ID: 19754358
[TBL] [Abstract][Full Text] [Related]
20. PDGF receptor-α promotes TGF-β signaling in hepatic stellate cells via transcriptional and posttranscriptional regulation of TGF-β receptors.
Liu C; Li J; Xiang X; Guo L; Tu K; Liu Q; Shah VH; Kang N
Am J Physiol Gastrointest Liver Physiol; 2014 Oct; 307(7):G749-59. PubMed ID: 25169976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
